Beraprost Sodium 314d Modified Release Tablets

DRUG2 trials

Sponsors

Lung Biotechnology PBC

Conditions

Pulmonary Arterial Hypertension

Phase 3

A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor

WithdrawnNCT01458236

Lung Biotechnology PBCPulmonary Arterial Hypertension

Start: 2011-11-30End: 2016-03-31Updated: 2012-05-14

Beraprost-314d Added-on to Tyvaso® (BEAT)

CompletedNCT01908699

Lung Biotechnology PBCPulmonary Arterial Hypertension

Start: 2013-05-31End: 2019-02-19Updated: 2020-08-03